InvestmentUpdated on 20 March 2025
GENBIOMA SERIES A
About
Funding type: Series A. Venture capital firms, strategic partners, and other institutional investors
Technology: Microbiome Science.
Platform to develop POSTBIOTICS as ingredients and nutritional supplements that regulate metabolism through the balance of the intestinal microbiota.
Our cutting-edge technology is based on the platform in C. elegans to quickly search new strains for metabolic disorders by targeting the gut microbiota. Inactivated strains for developing effective, safe and highly stable Postbiotics for Metabolic Health.
Therapeutic Area: Preventing Metabolic Disorders. Our first portfolio of microbiome solutions for people with type 2 diabetes, prediabetes and obesity. Postbiotic products to prevent and reverse disease progression.
Stage
- Expansion
- Growth and Establishment
Organisation
Similar opportunities
Product
POSTBIOTIC nutritional supplement for glucose control: Reglubetic(R)HI
- Distribution Partner
- Health Biotechnology
Josune Ayo
CoFounder & CEO at Genbioma Aplicaciones S.L.
Navarra, Navarra, Spain
Product
POSTBIOTIC nutritional supplement for glucose control: Reglubetic(R)HI
- Distribution Partner
- Health Biotechnology
Josune Ayo
CoFounder & CEO at Genbioma Aplicaciones S.L.
Navarra, Navarra, Spain
Product
pA1c®HI a Postbiotic ingredient for glucose metabolic health
- Distribution Partner
- Health Biotechnology
Josune Ayo
CoFounder & CEO at Genbioma Aplicaciones S.L.
Navarra, Navarra, Spain